Earnings ·
Dyne Therapeutics reported a net loss of $178.6 million, or $1.08 per share, for the quarter ended June 30, 2026…
DYNDyne Therapeutics, Inc.
Dyne Therapeutics reported a net loss of $178.6 million, or $1.08 per share, for the quarter ended June 30, 2026, compared to a $110.9 million loss in the prior year period. The company completed an underwritten public offering of 21,045,000 shares at $20.50 per share in July 2026, generating approximately $431 million in gross proceeds and $405 million in net proceeds. Cash, cash equivalents, and marketable securities stood at $898.5 million as of June 30, 2026, with expected runway into Q2 2028. Key regulatory milestones include FDA acceptance of the BLA for z-rostudirsen for exon 51 DMD with a PDUFA date of January 21, 2027, and Priority Review granted. The company also completed enrollment in the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1 and received FDA clearance for an IND for DYNE-302 in FSHD. Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for genetically driven neuromuscular diseases.